Biotech Values

[ghmm]

Appreciate the comments.

I would think this would not be an insurmountable target for some combination of Protease/polymerase with SOC and wonder why it is not pursued more? I wonder if the Boceprevir experience along with the fear of combining too many agents has put too much doubt on this possibility in the near term.

It would be curious if telaprevir does not have stellar PROVE-3 results but goes on to have comparable Phase 3 results in terms of both efficacy and safety (as Phase 2) while along the same time-line some other combination does get compelling results in earlier (phase 2) studies for some classification of patients for fail to get an SVR while having a more favorable safety profile. Would the FDA approve both in different patient populations or put the two drugs against each other possibly delaying one till it is further developed?